Association of plasma VEGF-A, soluble VEGFR-1 and VEGFR-2 levels and clinical response and survival in advanced colorectal cancer patients receiving bevacizumab with modified FOLFOX6

Aoyagi,Yoshiko; Iinuma,Hisae; Horiuchi,Atsushi; Shimada,Ryu; Watanabe,Toshiaki

doi:10.3892/ol_00000045

Association of plasma VEGF-A, soluble VEGFR-1 and VEGFR-2 levels and clinical response and survival in advanced colorectal cancer patients receiving bevacizumab with modified FOLFOX6

Authors:
- Yoshiko Aoyagi
- Hisae Iinuma
- Atsushi Horiuchi
- Ryu Shimada
- Toshiaki Watanabe
View Affiliations

Affiliations: Department of Surgery, Teikyo University School of Medicine, Tokyo 173-0003, Japan
Published online on: March 1, 2010 https://doi.org/10.3892/ol_00000045
Pages: 253-259

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

For individualized bevacizumab-based therapy, non-invasive biomarkers are necessary. This study assessed the predictive value of plasma vascular endothelial growth factor (VEGF)-A, soluble VEGF receptor (sVEGFR)-1 and sVEGFR-2 levels as biomarkers for clinical response and survival in advanced colorectal cancer (CRC) patients treated with bevacizumab and modified FOLFOX6 (mFOLFOX6). Forty-six unresectable advanced CRC patients and 20 healthy controls were included in this study. CRC patients were treated with bevacizumab and mFOLFOX6. Pretreatment plasma VEGF-A, sVEGFR-1 and sVEGFR-2 levels were measured using the multiplex immunoassay. Plasma VEGF-A, sVEGFR-1 and sVEGFR-2 levels were significantly higher in CRC patients than in the healthy subjects. The plasma sVEGFR-1 levels in the responder patients [complete response (CR)/partial response (PR)] and stable disease (SD) patients were significantly lower than those in the progressive disease (PD) patients (CR/PR vs. PD, p=0.025; SD vs. PD, p=0.032), while the plasma VEGF-A and sVEGFR-2 levels did not show any significant differences between the two groups of patients. Patients with higher sVEGFR-1 levels showed a significantly poorer progression-free survival (PFS) and overall survival (OS) than those with lower VEGFR-1 levels. In contrast, VEGF-A and sVEGFR-2 did not show any significant relationship between PFS and OS according to the status of each level. In the multivariate Cox proportional hazard regression analysis, sVEGFR-1 levels showed a significant relationship between PFS and OS. These results suggest that plasma sVEGFR-1 levels have a predictive value for clinical response and survival in advanced CRC patients treated with bevacizumab and mFOLFOX6. Larger scale studies are needed to further validate our results.

View Figures

View References

1	Hicklin DJ and Ellis LM: Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 23:1011–1027. 2005. View Article : Google Scholar : PubMed/NCBI
2	Hurwits H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med. 350:2335–2342. 2004. View Article : Google Scholar : PubMed/NCBI
3	Iwasaki J and Nihira S: Anti-angiogenic therapy against gastrointestinal tract cancers. Jpn J Clin Oncol. 16:1–9. 2009.
4	Yamaguchi K, Boku N, Kato K, Komatsu Y, Muro K and Hamamoto Y: Preliminary efficacy, safety and operability of bevacizumab plus capecitabine plus oxaliplatin (XELOX) as first-line therapy in Japanese patients with initially unresectable metastatic colorectal cancer. Ann Oncol. 19:viii1302008.
5	Karapetis CS, Khambata FS, Jonker DJ, et al: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 359:1757–1765. 2008. View Article : Google Scholar : PubMed/NCBI
6	Willett CG, Boucher Y, Duda DG, et al: Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a Phase I trial and rectal cancer patients. J Clin Oncol. 22:8136–8139. 2005. View Article : Google Scholar
7	Galizia G, Lieto E, Ferraraccio F, et al: Determination of molecular marker expression can predict clinical outcome in colon carcinoma. Clin Cancer Res. 10:3490–3499. 2004. View Article : Google Scholar : PubMed/NCBI
8	Takahashi Y, Kitadai Y, Bucana CD, Cleary KR and Ellis LM: Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity metastasis and proliferation of human colon cancer. Cancer Res. 55:3964–3968. 1995.PubMed/NCBI
9	Werther K, Christensen IJ and Nielsen HJ: Prognostic impact of matched preoperative plasma and serum VEGF in patients with primary colorectal carcinoma. Br J Cancer. 86:417–423. 2002. View Article : Google Scholar : PubMed/NCBI
10	Broll R, Erdmann H, Duchrow M, et al: Vascular endothelial growth factor (VEGF) – a valuable serum tumor marker in patients with colorectal cancer? Eur J Surg Oncol. 27:37–42. 2001.
11	Willett CG, Boucher Y, Duda DG, et al: Efficacy, safety and biomarkers of neoadjuvant bevacizumab, radiation therapy and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol. 18:3020–3026. 2009. View Article : Google Scholar : PubMed/NCBI
12	Denduluri N, Yang SX, Berman AW, Nguyen D, Liewehr DJ, Steinberg SM and Swalin SM: Circulating biomarkers of bevacizumab activity in patients. Cancer Biol Ther. 7:15–20. 2008. View Article : Google Scholar : PubMed/NCBI
13	Ferrara N and Alitalo K: Clinical application of angiogenic growth factors and their inhibitors. Nat Med. 5:1359–1364. 1999. View Article : Google Scholar : PubMed/NCBI
14	Shibuya M: Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct Func. 26:25–35. 2001. View Article : Google Scholar : PubMed/NCBI
15	Kendall RL and Thomas KA: Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA. 90:10705–10709. 1993. View Article : Google Scholar : PubMed/NCBI
16	Kendall RL, Wang G and Thomas KA: Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun. 226:324–328. 1996. View Article : Google Scholar : PubMed/NCBI
17	Harris AL, Reusch P, Barlenon B, Hang C, Dobbs N and Marme D: Soluble Tie2 and Flt1 extracellular domains in serum of patients with renal cancer and response to antiangiogenic therapy. Clin cancer Res. 7:1992–1997. 2001.PubMed/NCBI
18	Toi M, Bando H, Ogawa T, Muta M, Horing C and Weich HA: Significance of vascular endothelial growth factor (VEGF)/soluble VEGF receptor-1 relationship in breast cancer. Int J Cancer. 98:14–18. 2002. View Article : Google Scholar : PubMed/NCBI
19	Tas F, Duranyildiz D, Oguz H, Camlica H, Yasasever V and Topuz E: Circulating serum levels of angiogenic factors and vascular endothelial growth factor receptors 1 and 2 in melanoma patients. Melanoma Res. 16:405–411. 2006. View Article : Google Scholar : PubMed/NCBI
20	Yamaguchi T, Nando H, Mori T, et al: Overexpression of soluble vascular endothelial growth factor receptor 1 in colorectal cancer: association with progression and prognosis. Cancer Sci. 98:405–410. 2007. View Article : Google Scholar : PubMed/NCBI
21	Hu Q, Dey AL, Yang Y, et al: Soluble vascular endothelial growth factor receptor 1, and not receptor 2, is an independent prognostic factor in acute myeloid leukemia and myeloidysplastic syndromes. Cancer. 100:1884–1891. 2004. View Article : Google Scholar : PubMed/NCBI
22	Hormbrey E, Gillespie P, Turner K, Han C, Roberts A, McGrouther D and Harris AL: A critical review of vascular endothelial growth factor (VEGF) analysis in peripheral blood: is the current literature meaningful? Clin Exp Metastasis. 19:651–663. 2002. View Article : Google Scholar : PubMed/NCBI
23	Otrock ZK, Makarem JA and Shamseddine AI: Vascular endothelial growth factor family of ligands and receptors: review. Blood Cells Mol Dis. 38:258–268. 2007. View Article : Google Scholar : PubMed/NCBI
24	Poon RT, Fan ST and Wong J: Clinical implication of circulating angiogenic factors in cancer patients. J Clin Oncol. 19:1207–1225. 2001.PubMed/NCBI
25	Burstein A, Chen Y-H and Parker LM: VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy. Clin Cancer Res. 14:7871–7877. 2008. View Article : Google Scholar : PubMed/NCBI
26	Holden SN, Ryan E, Kearns A, Holmgren E and Hurwitz H: Benefit from bevacizumab (BV) is independent of pretreatment plasma vascular endothelial growth factor-A (pl-VEGF) in patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol. 123:35552005.
27	Olsson AK, Dimberg A, Kreuger J and Claesson-Welsh L: VEGF receptor signaling – in control of vascular function. Nat Rev Mol Cell Biol. 7:359–371. 2006.
28	Herold MC, Steiner HH, Andl T, et al: Expression and functional significance of vascular endothelial growth factor receptors in human tumor cells. Lab Invest. 79:1573–1582. 1999.PubMed/NCBI
29	Masood R, Cai J, Zheng T, Smith DL, Hinton DR and Gill PS: Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. Blood. 98:1904–1913. 2001. View Article : Google Scholar : PubMed/NCBI
30	Ferrara N, Gerber HP and LeCouter J: The biology of VEGF and its receptors. Nat Med. 9:669–676. 2003. View Article : Google Scholar : PubMed/NCBI
31	Holash J, Davis S, Papadopoulos N, et al: VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA. 99:11393–11398. 2003. View Article : Google Scholar : PubMed/NCBI
32	Wierzbowska A, Robak T, Wizesien-Kus A, Krawczynska A, Maranda EL and Urbanska-Rys H: Circulating VEGF and its soluble receptors sVEGFR-1 and sVEGFR-2 in patients with acute leukemia. Eur Cytokine Netw. 14:149–153. 2003.PubMed/NCBI
33	AI-Moundhri M, Shukaili A, AI-Nabhani M, AI-Bahrani B, Burney IA, Rozovo A and Ganguly SS: Measurement of circulating levels of VEGF-A, -C and -D and their receptors, VEGFR-1 and -2 in gastric adenocarcinoma. World Gastroenterol. 14:3879–3883. 2008. View Article : Google Scholar : PubMed/NCBI
34	Ustuner Z, Saip P, Yasasever V, et al: Prognostic and predictive value of vascular endothelial growth factor and its soluble reseptor VEGFR-1 and VEGFR-2 levels in the sera of small cell lung cancer patients. Med Oncol. 25:394–399. 2008. View Article : Google Scholar : PubMed/NCBI